---
input_text: 'Canavan disease: a monogenic trait with complex genomic interaction.
  Canavan disease (CD) is an inherited leukodystrophy, caused by aspartoacylase (ASPA)
  deficiency, and accumulation of N-acetylaspartic acid (NAA) in the brain. The gene
  for ASPA has been cloned and more than 40 mutations have been described, with two
  founder mutations among Ashkenazi Jewish patients. Screening of Ashkenazi Jews for
  these two common mutations revealed a high carrier frequency, approximately 1/40,
  so that programs for carrier testing are currently in practice. The enzyme deficiency
  in CD interferes with the normal hydrolysis of NAA, which results in disruption
  of myelin and spongy degeneration of the white matter of the brain. The clinical
  features of the disease are macrocephaly, head lag, progressive severe mental retardation,
  and hypotonia in early life, which later changes to spasticity. A knockout mouse
  for CD has been generated, and used to study the pathophysiological basis for CD.
  Findings from the knockout mouse indicate that this monogenic trait leads to a series
  of genomic interaction in the brain. Changes include low levels of glutamate and
  GABA. Microarray expression analysis showed low level of expression of GABA-A receptor
  (GABRA6) and glutamate transporter (EAAT4). The gene Spi2, a gene involved in apoptosis
  and cell death, showed high level of expression. Such complexity of gene interaction
  results in the phenotype, the proteome, with spongy degeneration of the brain and
  neurological impairment of the mouse, similar to the human counterpart. Aspartoacylase
  gene transfer trial in the mouse brain using adenoassociated virus (AAV) as a vector
  are encouraging showing improved myelination and decrease in spongy degeneration
  in the area of the injection and also beyond that site.'
raw_completion_output: |-
  primary_disease: Canavan disease

  medical_actions: Screening for mutations; Carrier testing; Aspartoacylase gene transfer trial using adenoassociated virus (AAV) as a vector

  symptoms: Macrocephaly; Head lag; Progressive severe mental retardation; Hypotonia; Spasticity

  chemicals: N-acetylaspartic acid (NAA); Glutamate; GABA; GABRA6; EAAT4

  action_annotation_relationships: Screening for mutations PREVENTS progressive severe mental retardation IN Canavan disease; Carrier testing PREVENTS progressive severe mental retardation IN Canavan disease; Aspartoacylase gene transfer trial using adenoassociated virus (AAV) as a vector TREATS spongy degeneration of the brain IN Canavan disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Aspartoacylase gene transfer trial using adenoassociated virus (AAV) as a vector TREATS spongy degeneration of the brain IN Canavan disease

  ===

extracted_object:
  primary_disease: MONDO:0010079
  medical_actions:
    - Screening for mutations
    - Carrier testing
    - Aspartoacylase gene transfer trial using adenoassociated virus (AAV) as a vector
  symptoms:
    - HP:0000256
    - HP:0032988
    - Progressive severe mental retardation
    - HP:0001252
    - HP:0001257
  chemicals:
    - CHEBI:21547
    - CHEBI:29987
    - CHEBI:16865
    - GABRA6
    - EAAT4
  action_annotation_relationships:
    - subject: Screening
      predicate: PREVENTS
      object: progressive severe mental retardation
      qualifier: MONDO:0010079
      object_qualifier: severe
      subject_extension: mutations
    - subject: Carrier testing
      predicate: PREVENTS
      object: Progressive severe mental retardation
      qualifier: MONDO:0010079
      object_qualifier: Severe
    - subject: gene transfer trial
      predicate: TREATS
      object: spongy degeneration of the brain
      qualifier: MONDO:0010079
      subject_qualifier: using adenoassociated virus (AAV) as a vector
      subject_extension: aspartoacylase gene transfer
named_entities:
  - id: MONDO:0010079
    label: Canavan disease
  - id: MONDO:0003847
    label: Genetic disorders
  - id: HP:0000739
    label: Anxiety
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:16953
    label: N-acetyl-L-aspartate
  - id: CHEBI:76720
    label: antisense oligonucleotide
  - id: MONDO:0019052
    label: Inborn errors of metabolism (IEM)
  - id: CHEBI:35584
    label: Purines
  - id: CHEBI:16898
    label: Pyrimidines
  - id: CHEBI:35692
    label: Dicarboxylic acids
  - id: CHEBI:16040
    label: Cytosine
  - id: CHEBI:17562
    label: Cytidine
  - id: CHEBI:16737
    label: Creatinine
  - id: CHEBI:17568
    label: Uracil
  - id: CHEBI:16704
    label: Uridine
  - id: CHEBI:17802
    label: Beta-pseudouridine
  - id: CHEBI:16708
    label: Adenine
  - id: CHEBI:38635
    label: 3-methyladenine
  - id: CHEBI:17368
    label: Hypoxanthine
  - id: CHEBI:15318
    label: Xanthine
  - id: CHEBI:18107
    label: Xanthosine
  - id: CHEBI:17596
    label: Inosine
  - id: CHEBI:16750
    label: Guanosine
  - id: CHEBI:22652
    label: Ascorbic acid
  - id: CHEBI:17821
    label: Thymine
  - id: CHEBI:17748
    label: Thymidine
  - id: CHEBI:27226
    label: Uric acid
  - id: CHEBI:68441
    label: 1-methyluric acid
  - id: CHEBI:16742
    label: Orotic acid
  - id: CHEBI:76931
    label: N-acetylaspartylglutamate
  - id: CHEBI:30794
    label: Malonic acid
  - id: CHEBI:30860
    label: Methylmalonic acid
  - id: CHEBI:16856
    label: GSH
  - id: CHEBI:17858
    label: GSSG
  - id: CHEBI:30145
    label: lithium
  - id: MONDO:0019046
    label: leukodystrophies
  - id: MAXO:0000127
    label: genetic testing
  - id: MAXO:0009004
    label: whole exome sequencing (WES)
  - id: MAXO:0000079
    label: genetic counseling
  - id: HP:0000256
    label: Macrocephaly
  - id: HP:0001249
    label: Mental retardation
  - id: HP:0001252
    label: Hypotonia
  - id: CHEBI:21547
    label: N-acetylaspartic acid
  - id: CHEBI:27881
    label: Resveratrol (RSV)
  - id: HP:0001355
    label: Megalencephaly
  - id: HP:0001263
    label: Developmental delay
  - id: MAXO:0000068
    label: Transplantation
  - id: MONDO:0011925
    label: merosin-negative congenital muscular dystrophy
  - id: MAXO:0000387
    label: muscle biopsy
  - id: HP:0002350
    label: cerebellar cysts
  - id: CHEBI:33375
    label: gadolinium
  - id: HP:0001250
    label: Seizures
  - id: HP:0000750
    label: Speech delay
  - id: CHEBI:15354
    label: Choline
  - id: MONDO:0019262
    label: Batten disease
  - id: MONDO:0005180
    label: Parkinson's disease
  - id: MONDO:0008752
    label: Alexander disease
  - id: MONDO:0011380
    label: CACH/VWM
  - id: HP:0003819
    label: death in childhood
  - id: HP:0000407
    label: sensorineural hearing loss
  - id: MONDO:0010100
    label: Tay-Sachs disease
  - id: MONDO:0008876
    label: Bloom syndrome
  - id: MONDO:0009061
    label: cystic fibrosis
  - id: MONDO:0009131
    label: familial dysautonomia
  - id: MONDO:0009653
    label: mucolipidosis type IV
  - id: HP:0010864
    label: severe mental retardation
  - id: CHEBI:73688
    label: N-acetylaspartylglutamic acid
  - id: HP:0002415
    label: Leukodystrophies
  - id: HP:0003269
    label: Pelizaeus-Merzbacher disease
  - id: MONDO:0005648
    label: Autosomal recessive (AR) conditions; Autosomal dominant (AD) conditions;
      X-linked (XL) conditions
  - id: MAXO:0000530
    label: Genetic carrier screening
  - id: MONDO:0005071
    label: neurologic disease
  - id: CHEBI:9661
    label: Glyceryl triacetate
  - id: CHEBI:30089
    label: Acetate
  - id: CHEBI:22660
    label: Aspartic acid
  - id: MAXO:0009003
    label: preimplantation genetic diagnosis (PGD)
  - id: CHEBI:15366
    label: Acetic acid
  - id: CHEBI:18237
    label: Glutamic acid
  - id: MAXO:0001001
    label: gene therapy
  - id: CHEBI:157802
    label: Creatine (Cr)
  - id: CHEBI:53620
    label: Myo-Inositol (mI)
  - id: CHEBI:24996
    label: Lactate
  - id: CHEBI:16813
    label: Galactitol
  - id: CHEBI:22918
    label: Branched chain amino acids
  - id: MONDO:0018660
    label: Hemophilia
  - id: MONDO:0013282
    label: Alpha-1-antitrypsin Deficiency
  - id: CHEBI:17053
    label: l-aspartic acid
  - id: HP:0000952
    label: Jaundice
  - id: HP:0001942
    label: Metabolic acidosis
  - id: HP:0012734
    label: Ketotic hypoglycemia
  - id: HP:0001987
    label: Hyperammonemia
  - id: CHEBI:132943
    label: Aspartate
  - id: HP:0000618
    label: vision impairment
  - id: HP:0001141
    label: severe vision loss
  - id: HP:0000510
    label: Retinitis pigmentosa
  - id: HP:0032988
    label: Head lag
  - id: HP:0001257
    label: Spasticity
  - id: CHEBI:29987
    label: Glutamate
  - id: CHEBI:16865
    label: GABA
